Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas

Journal of Plastic, Reconstructive and Aesthetic Surgery

Volumn 64, Issue 4, 2011, Pages 445-451

  Holmes, W J M ^a   Mishra, A ^a   Gorst, C ^a   Liew, S H ^a  

^a ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Beta blocker; Haemangioma; Haemangioma treatment; Hemangioma; Infantile; Propranolol

Indexed keywords

PROPRANOLOL;

CAPILLARY HEMANGIOMA; CHILD; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PREMEDICATION; PRESCHOOL CHILD; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; FACIAL NEOPLASMS; FEMALE; HEMANGIOMA; HUMANS; INFANT; MALE; PROPRANOLOL; PROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 79952696987     PISSN: 17486815     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bjps.2010.07.009     Document Type: Conference Paper

References (42)

1. Enjolras O, Gelbert F. Superficial hemangiomas: associations and management. Pediatr Dermatol 1997 May-Jun;14:173-9. (Pubitemid 27255859)
2. Enjolras O, Mulliken JB. Vascular tumors and vascular malformations. Adv Dermatol 1997;13:375-423 (new issues).
3. Baetz J, Eigelshoven S, Marquard J, et al. Infantile hemangioma. Successful treatment with propranolol. Hautarzt 2010 Apr;61:290-2.
4. Zimmerman AP, Wiegand S, Werner JA, et al. Propranolol therapy for infantile haemangiomas: review of the literature. Int J Pediatr Otorhinolaryngol 2010;74(4):338-42.
5. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Eng J Med. 2008;358(24):2649-51. (Pubitemid 351831393)
6. Frieden IJ, Haggstrom AN, Drolet BA, et al. Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7-9, 2005, Bethesda, Maryland, USA. Pediatr Dermatol 2005 Sep-Oct;22:383-406. (Pubitemid 43960991)
7. Haggstrom AN, Lammer EJ, Schneider RA, et al. Patterns of infantile hemangiomas: new clues to hemangioma pathogenesis and embryonic facial development. Pediatrics 2006;117(3):698-703. (Pubitemid 46063211)
8. Enjolras O. Classification and management of the various superficial vascular anomalies: hemangiomas and vascular malformations. J Dermatol 1997 Nov;24:701-10. (Pubitemid 28030715)
9. Metz BJ, Rubenstein MC, Levy ML, et al. Response of ulcerated perineal hemangiomas of infancy to becaplermin gel, a recombinant human platelet-derived growth factor. Arch Dermatol 2004 Jul;140:867-70. (Pubitemid 38917857)
10. Frieden IJ, Eichenfield LF, Esterly NB, et al. Guidelines of care for hemangiomas of infancy. American Academy of Dermatology Guidelines/Outcomes Committee. J Am Acad Dermatol 1997 Oct;37:631-7.
11. Bennett ML, Fleischer Jr AB, Chamlin SL, et al. Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol 2001 Sep;137:1208-13. (Pubitemid 32847844)
12. Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg 1999;104(6):1616-23. (Pubitemid 29510480)
13. George ME, Sharma V, Jacobson J, et al. Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas. Arch Dermatol 2004;140(8):963-9. (Pubitemid 39062647)
14. Lomenick JP, Reifschneider KL, Lucky AW, et al. Prevalence of adrenal insufficiency following systemic glucocorticoid therapy in infants with hemangiomas. Arch Dermatol 2009 Mar;145:262-6.
15. Constantinides Y, Gorst C, Didi M, Liew S. Adrenal suppression after steroid treatment of infantile hemangioma. Poster presentation at the 18th International Workshop on Vascular Anomalies. [Poster]. 2010.
16. Denoyelle F, Leboulanger N, Enjolras O, et al. Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma. Int J Pediatr Otorhinolaryngol; 2009:1168-72.
17. Buckmiller L. Propranolol treatment for infantile hemangiomas. Current opinion in otolaryngology & head and neck surgery; 2009 Oct 23.
18. Holmes WJM, Mishra A, Gorst C, et al. Propranolol as first-line treatment for infantile hemangiomas. Plastic and Reconstructive Surgery 2010 Jan 1;125(1):420-1.
19. Jephson C, Manunza F, Syed S, et al. Successful treatment of isolated subglottic haemangioma with propranolol alone. Int J Pediatr Otorhinolaryngol; 2009 Sep 29.
20. Sans V, De La Roque ED, Berge J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics 2009 Sep 1;124(3):e423-31.
21. Michel JL, Patural H. Response to oral propranolol therapy for ulcerated hemangiomas in infancy. Arch Pediatr 2009 Dec;16 (12):1565-8.
22. Theletsane T, Redfern A, Raynham O, et al. Life-threatening infantile haemangioma: a dramatic response to propranolol. J Eur Acad Dermatol Venereol 2009 Dec 1;23(12):1465-6.
23. Marsciani A, Pericoli R, Alaggio R, et al. Massive response of severe infantile hepatic hemangioma to propanolol. Pediatr Blood Cancer 2010 Jan 1;54(1):176.
24. Fay A, Nguyen J, Jakobiec FA, et al. Propranolol for isolated orbital infantile hemangioma. Arch Ophthalmol 2010 Feb 1; 128(2):256-8.
25. Qin ZP, Liu XJ, Li KL, et al. Treatment of infantile hemangiomas with low-dose propranolol: evaluation of short-term efficacy and safety. Zhonghua Yi Xue Za Zhi 2009 Dec 1;89:3130-4.
26. O T, Waner M, Xu D, Shatava A, Blei F, Ward D, et al. Vandetanib and prorpanolol inhibit Infantile Hemangioma (IH) and NICH Cell growth in vitro. Oral presentation at the 18th International Workshop on Vascular Anomalies. [Oral Presentation]. 2010.
27. Yang Q, Kumar S, Salalto V, Szabo S, North PE. Prorpanolol inhibits proliferation and tube formation by purified placental capillary endothelial cells, an in vitro model for infantile hemangioma (IH), and induces their apoptosis. Oral presentation at the 18th International Workshop on Vascular Anomalies. [Oral Presentation]. 2010 23/04/2010.
28. Bruckner AL, Frieden IJ. Hemangiomas of infancy. J Am Acad Dermatol 2003 Apr;48:477-93. quiz 94-6.
29. Bigorre M, Van Kien AK, Valette H. Beta-blocking agent for treatment of infantile hemangioma. Plast Reconstr Surg 2009 Jun;123:195e-6e.
30. Shashidhar H, Langhans N, Grand RJ. Propranolol in prevention of portal hypertensive hemorrhage in children: a pilot study. J Pediatr Gastroenterol Nutr 1999 Jul;29:12-7. (Pubitemid 30345821)
31. Zacharias FJ. Patient acceptability of propranolol and the occurence of side effects. Postgrad Med J 1976;52:87-9.
32. Artman M, Grayson M, Boerth RC. Propranolol in children: safety-toxicity. Pediatrics 1982 Jul;70:30-1. (Pubitemid 12078070)
33. Love JN, Sikka N. Are 1-2 tablets dangerous? Beta-blocker exposure in toddlers. J Emerg Med 2004 Apr 1;26(3):309-14. (Pubitemid 38340830)
34. Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol 2009 Jan 1;26(5):610-4.
35. Storch CH, Hoeger PH. Propranolol for infantile haemangiomas - insights into the molecular mechanisms of action. Br J Dermatol; 2010 May 8.
36. Iaccarino G, Ciccarelli M, Sorriento D, et al. Ischemic neoangiogenesis enhanced by beta2-adrenergic receptor overexpression: a novel role for the endothelial adrenergic system. Circ Res. 2005 Nov 25;97(11):1182-9.
37. Takahashi K, Mulliken JB, Kozakewich HP, et al. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994 Jun 1;93(6):2357-64. (Pubitemid 24177146)
38. Tan ST, Velickovic M, Ruger BM, et al. Cellular and extracellular markers of hemangioma. Plast Reconstr Surg 2000 Sep 1;106 (3):529-38. (Pubitemid 30666290)
39. Hattori Y, Yamamoto S, Matsuda N. Sympathetic control of VEGF angiogenic signaling: dual regulations by alpha 2-adrenoceptor activation? Circ Res. 2007 Sep 28;101(7):642-4.
40. Fredriksson JM, Lindquist JM, Bronnikov GE, et al. Norepinephrine induces vascular endothelial growth factor gene expression in brown adipocytes through a beta -adrenoreceptor/ cAMP/protein kinase A pathway involving Src but independently of Erk1/2. J Biol Chem. 2000 May 5;275(18):13802-11. (Pubitemid 30257453)
41. Woolard J, Wang WY, Bevan HS, et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004 Nov 1;64:7822-35. (Pubitemid 39446915)
42. Pritchard-Jones RO, Dunn DB, Qiu Y, et al. Expression of VEGF (xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma. Br J Cancer 2007 Jul 16;97:223-30. (Pubitemid 47057469)